Group 1 - The company Sichuan Enwei Pharmaceutical Co., Ltd. has recently obtained a renewed Drug Production License from the drug regulatory authority [1] - The renewed license is valid until July 17, 2030, and covers various forms of medication including ointments, granules, tablets, and traditional Chinese medicine [1] - The company has authorized Hunan Taiyang Pharmaceutical Co., Ltd. to produce its exclusive product, Jiangnao Pain Relief Liniment, with a change in the classification code [1][2] Group 2 - The production of Jiangnao Pain Relief Liniment is expected to enhance the company's product structure, meet market demand, and positively impact revenue and profit metrics [2] - The product is indicated for the auxiliary treatment of local pain and swelling caused by rheumatic arthritis, showcasing its therapeutic benefits [2]
恩威医药股份有限公司 关于全资子公司取得换发的《药品生产许可证》的公告